Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
7 affiliations
- 1Faculty of Health Service, Naval Medical University, Shanghai, 200433, China.
- 2Faculty of Naval Medicine, Naval Medical University, Shanghai, 200433, China.
- 3Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
- 4Department of Anesthesiology, Naval Medical Center, Naval Medical University, Shanghai, 200052, China.
- 5Faculty of Health Service, Naval Medical University, Shanghai, 200433, China. [email protected].
- 6Department of Health Statistics, Naval Medical University, No. 800 Xiangyin Road, Shanghai, 200433, China. [email protected].
- 7Faculty of Health Service, Naval Medical University, Shanghai, 200433, China. [email protected].
Abstract
Objective
Concerns regarding neuropsychiatric adverse events (NPAEs), including depression and suicidality, have emerged with the expanding use of GLP-1-based therapies across metabolic and weight-management indications. This study aimed to characterize neuropsychiatric adverse-event reporting patterns for GLP-1-based therapies in VigiBase using disproportionality analysis.Methods
Individual case safety reports entered into the WHO global pharmacovigilance database (VigiBase) from inception through 31 January 2025 were examined. Disproportionality analysis using the information components and the reporting odds ratio was conducted to identify putative safety signals. The full VigiBase reporting background during the study period was used as the comparator. We described the drug-event pairs, mapped signal overlap across agents, evaluated the relationship between reporting frequency and signal magnitude, and conducted stratified analyses by sex and age.Results
Among 899 280 GLP-1RAs-related reports, 19 811 (2.2%) related NPAEs comprised 273 preferred terms and generated 69 positive signals. Semaglutide and liraglutide presented the broadest and most potent signal portfolios, driven chiefly by binge eating (semaglutide, IC₀₂₅ = 3.379; ROR₀₂₅ = 14.483), and aversion (liraglutide, IC₀₂₅ = 3.365; ROR₀₂₅ = 20.512). In contrast, albiglutide was essentially signal negative, and dulaglutide and tirzepatide generated narrower spectra. In addition, semaglutide was positively associated with two "suicide/self-injury" AEs: "depression suicidal" (ROR₀₂₅ = 4.822) and "suicidal ideation" (ROR₀₂₅ = 2.643).Conclusions
This study identified several potential drug safety signals. However, the estimates were unadjusted and may be influenced by confounding by indication, channelling, notoriety bias, and event competition. Eating-related signals should be interpreted cautiously because they may overlap with the treated population and appetite-related pharmacology of these agents. Given the spontaneous reporting nature of VigiBase, these findings should be interpreted as potential reporting signals rather than evidence of causality. Further well-designed observational studies and prospective clinical investigations are needed to clarify whether GLP-1-based therapies are associated with increased neuropsychiatric risk and to identify patient-level risk modifiers.
Related
- Hepatobiliary adverse-event reporting patterns for endocrine therapies in breast cancer: a pharmacovigilance study based on FAERS and VigiAccess
- Semaglutide and Panic Attacks: Active‐Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post‐Marketing Pharmacovigilance
- Post-Marketing Reporting Patterns of Ceftazidime–Avibactam and Ceftolozane–Tazobactam: Analysis of Adverse Event Reports from EudraVigilance
- Adverse Drug Reaction Reporting Among Herbal Practitioners: A Mixed-Methods Study of Reporting Practices, Associated Factors, and Pharmacovigilance System Barriers in the Greater Accra Region, Ghana
- A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide
BibTeX
@article{liang2026neuropsychiatric,
title = {{Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).}},
author = {Jizhou Liang and Lulong Bo and Xiaoyong Miao and Xiaojing Guo and Jinfang Xu and Jia He and Xiaofei Ye},
journal = {BMC pharmacology \& toxicology},
year = {2026},
month = jul,
doi = {10.1186/s40360-026-01190-4},
url = {https://europepmc.org/article/MED/42928322},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).
AU - Jizhou Liang
AU - Lulong Bo
AU - Xiaoyong Miao
AU - Xiaojing Guo
AU - Jinfang Xu
AU - Jia He
AU - Xiaofei Ye
PY - 2026
DA - 2026/07/28
JO - BMC pharmacology & toxicology
DO - 10.1186/s40360-026-01190-4
UR - https://europepmc.org/article/MED/42928322
AB - Objective Concerns regarding neuropsychiatric adverse events (NPAEs), including depression and suicidality, have emerged with the expanding use of GLP-1-based therapies across metabolic and weight-management indications. This study aimed to characterize neuropsychiatric adverse-event reporting patterns for GLP-1-based therapies in VigiBase using disproportionality analysis.Methods Individual case safety reports entered into the WHO global pharmacovigilance database (VigiBase) from inception through 31 January 2025 were examined. Disproportionality analysis using the information components and the reporting odds ratio was conducted to identify putative safety signals. The full VigiBase reporting background during the study period was used as the comparator. We described the drug-event pairs, mapped signal overlap across agents, evaluated the relationship between reporting frequency and signal magnitude, and conducted stratified analyses by sex and age.Results Among 899 280 GLP-1RAs-related reports, 19 811 (2.2%) related NPAEs comprised 273 preferred terms and generated 69 positive signals. Semaglutide and liraglutide presented the broadest and most potent signal portfolios, driven chiefly by binge eating (semaglutide, IC₀₂₅ = 3.379; ROR₀₂₅ = 14.483), and aversion (liraglutide, IC₀₂₅ = 3.365; ROR₀₂₅ = 20.512). In contrast, albiglutide was essentially signal negative, and dulaglutide and tirzepatide generated narrower spectra. In addition, semaglutide was positively associated with two "suicide/self-injury" AEs: "depression suicidal" (ROR₀₂₅ = 4.822) and "suicidal ideation" (ROR₀₂₅ = 2.643).Conclusions This study identified several potential drug safety signals. However, the estimates were unadjusted and may be influenced by confounding by indication, channelling, notoriety bias, and event competition. Eating-related signals should be interpreted cautiously because they may overlap with the treated population and appetite-related pharmacology of these agents. Given the spontaneous reporting nature of VigiBase, these findings should be interpreted as potential reporting signals rather than evidence of causality. Further well-designed observational studies and prospective clinical investigations are needed to clarify whether GLP-1-based therapies are associated with increased neuropsychiatric risk and to identify patient-level risk modifiers.
SN - 2050-6511
ER -